ESMO Asia 2025: key results and trends
What the 602 abstracts at ESMO Asia 2025 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.
- abstracts
- 602
- drug-linked abstracts
- 301
- companies
- 90
- from Phase 3 studies
- 42
Drug-linked abstracts by phase
- Phase 1 21
- Phase 1/2 16
- Phase 2 73
- Phase 2/3 2
- Phase 3 42
- Phase 4 2
Key results
Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue
encorafenib
199MO First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study
Read the abstract (opens in a new tab)Median PFS by BICR was 14.0 vs 7.1 mo, and median OS was not estimable (NE) vs 13.7 mo for EC+mFOLFOX6 vs control.
tisotumab vedotin
609MO Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301
Read the abstract (opens in a new tab)Median (95% CI) OS was not reached (9.7 months–not estimable) with TV vs 10.7 months (6.0-not estimable) with chemotherapy (HR 0.55; 95% CI 0.27–1.15).
retlirafusp alfa
298P SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ≥1: A post-hoc analysis of a phase III study
Read the abstract (opens in a new tab)Median OS was 16.7 months (95% CI, 14.4-18.5) in the SHR-1701 group versus 10.3 months (95% CI, 9.3-12.1) in the placebo group (HR=0.56; 95% CI, 0.45-0.71).
plinabulin
979MO Plinabulin/docetaxel vs. docetaxel in 2L/3L EGFRwt NSCLC after platinum regimens (DUBLIN-3): Asian subgroup analysis
Read the abstract (opens in a new tab)At 24-months (Mo) follow-up after database lock (DB), the survival benefit persisted with mOS favoring DP (10.8 vs. 8.8 Mo, HR=0.80, p=0.0300), and more pronounced in non-squamous (NSQ) pts (11.4 vs. 8.4 Mo, HR=0.69, p=0.0064).
lurbinectedin
980MO Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC): IMforte Asia subgroup results
Read the abstract (opens in a new tab)At data cutoff (29 Jul 2024), IRF-PFS was improved with lurbi + atezo vs atezo (median, 6.3 vs 1.8 mo; unstratified HR, 0.48; 95% CI: 0.27, 0.87), as was OS (median, 16.5 vs 12.2 mo; unstratified HR, 0.81; 95% CI: 0.37, 1.75).
dabrafenib + trametinib
1165P Safety profile of dabrafenib plus trametinib (D+T) in previously treated Chinese Mainland subgroup (CMS) population with radioactive iodine (RAI)–refractory BRAF V600E mutation–positive differentiated thyroid cancer (DTC)
Read the abstract (opens in a new tab)The incidence of grade ≥3 AEs was higher in the D+T (52.8%) than the PBO arm (21.7%).
surufatinib
375P Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II/III study
Read the abstract (opens in a new tab)With the median PFS follow-up duration of 8.15 months (m), S+C+AG demonstrated superior median PFS vs AG (7.20m vs 5.52m, stratified hazard ratio [HR] 0.499, log-rank P = 0.0407).
adebrelimab
277MO Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma
Read the abstract (opens in a new tab)The ASO group achieved significantly higher pCR rates compared to PSO group (25.45% vs 1.82%, p<0.0001), with marked tumor downstaging (ypT0: 25.45% vs 1.82%; ypN0: 65.45% vs 21.82%, both p<0.0001).
fruquintinib
205P Fruquintinib combined with TAS-102 with or without SBRT as third- or later-line treatment in metastatic colorectal cancer : Preliminary results from a prospective phase II trial
Read the abstract (opens in a new tab)ORR was 36.4% (4/11) in FTS vs 12% (3/25) in FT,and mPFS was not reached in FTS vs 8.58 months (95% CI: 4.57–9.00) in FT.
zongertinib
986P Zongertinib in HER2-mutant advanced NSCLC: Impact of therapy line on efficacy
Read the abstract (opens in a new tab)In patients who received 3L zongertinib, the confirmed ORR was 75.0% (46.8–91.1)
Trends at ESMO Asia 2025
Small molecules were the most frequent modality (51% of drug-linked abstracts). PDCD1 was the most frequent target (18%). Non-small cell lung cancer (NSCLC) was the most frequent disease (26%).
What the abstracts covered
Share of the 301 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.
- Antibody-drug conjugates9%28 drug-linked abstracts
- Bispecific antibodies5%14 drug-linked abstracts
Top targets
- PDCD15518%
- EGFR3110%
- ERBB2269%
- CD274238%
- MET145%
- VEGFR2145%
- VEGFR4145%
- TUBB134%
- VEGFR-1134%
- RET124%
Top modalities
- Small molecules15351%
- Monoclonal antibodies9030%
- Antibody-drug conjugates289%
- Bispecific antibodies145%
- Non-antibody therapeutic proteins72%
- Natural-product mixtures and botanicals62%
- Peptides52%
- Vaccines31%
Top diseases
- Non-small cell lung cancer (NSCLC)7826%
- Breast cancer3411%
- Gastric cancer (GC)186%
- Hepatocellular carcinoma (HCC)155%
- Head and neck squamous cell carcinoma (HNSCC)134%
- Gastric adenocarcinoma93%
- Gastroesophageal junction adenocarcinoma93%
- Prostate cancer (PCa)93%
- Colorectal cancer (CRC)83%
- Pancreatic cancer (PC)83%
Most active companies
- AstraZeneca279%
- Bristol Myers Squibb186%
- Merck165%
- Genentech103%
- Pfizer103%
- HUTCHMED93%
- Jiangsu HengRui Medicine Co., Ltd.93%
- Eisai83%
- Henlius83%
- BeiGene72%
Explore every ESMO Asia 2025 result in Gosset
All 301 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.
This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.